Venetoclax 10mg, 50mg, 100mg Tablets — BCL-2 Inhibitor for CLL, SLL and AML
Venclexta® (Venetoclax) — Targeted BCL-2 Inhibitor for Blood Cancers
Breakthrough Treatment for Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Venclexta® (Venetoclax) is a first-in-class BCL-2 inhibitor approved for the treatment of Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML). It works by blocking the BCL-2 protein that cancer cells use to survive and resist treatment, restoring the natural process of programmed cell death.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Venclexta (Venetoclax) to hospitals, oncology centres, clinics, and pharmacies across India. Manufactured by AbbVie Inc., one of the world’s leading oncology pharmaceutical companies, Venclexta represents a major breakthrough in the treatment of haematological malignancies.
What is Venclexta (Venetoclax)?
Venclexta contains Venetoclax, a selective BCL-2 (B-cell lymphoma 2) inhibitor. BCL-2 is a protein that is overexpressed in certain cancers including CLL, SLL, and AML. In healthy cells, BCL-2 helps regulate programmed cell death (apoptosis). In cancer cells, overexpression of BCL-2 prevents cells from dying naturally, allowing them to accumulate and grow uncontrollably.
By blocking BCL-2, Venetoclax releases death-triggering proteins inside cancer cells, initiating apoptosis and causing cancer cells to die. This targeted mechanism of action makes Venclexta a more precise treatment compared to conventional chemotherapy.
Full prescribing information is available at the FDA label for Venetoclax.
Clinical Studies and Evidence
Venclexta’s effectiveness is backed by extensive Phase 3 clinical trial data across multiple cancer types.
CLL14 Trial (Venetoclax + Obinutuzumab for Previously Untreated CLL) Published in the New England Journal of Medicine (2019), the CLL14 trial showed that Venetoclax plus Obinutuzumab significantly improved progression-free survival compared to Chlorambucil plus Obinutuzumab, with a 2-year PFS rate of 88.2% vs 64.1%.
MURANO Trial (Venetoclax + Rituximab for Relapsed/Refractory CLL) Published in the New England Journal of Medicine (2018), the MURANO trial showed Venetoclax plus Rituximab achieved a progression-free survival benefit of 85% at 12 months compared to 36.3% for Bendamustine plus Rituximab.
VIALE-A Trial (Venetoclax + Azacitidine for Newly Diagnosed AML) Published in the New England Journal of Medicine (2020), the VIALE-A trial demonstrated that Venetoclax plus Azacitidine significantly improved overall survival compared to Azacitidine alone in patients with newly diagnosed AML who were ineligible for intensive chemotherapy, with a median overall survival of 14.7 months vs 9.6 months.
AMPLIFY Trial (Venetoclax + Acalabrutinib for CLL) The Phase III AMPLIFY trial showed that the all-oral fixed-duration combination of Venetoclax plus Acalabrutinib achieved 77% of patients progression-free at three years, significantly outperforming chemoimmunotherapy. This combination represents the first all-oral, fixed-duration treatment for CLL and SLL.
Available Strengths
Venclexta is available in the following strengths:
Treatment follows a dose ramp-up schedule starting at 20mg daily in week 1, increasing gradually to the target maintenance dose of 400mg daily over 5 weeks. This gradual increase is essential to reduce the risk of tumour lysis syndrome (TLS).
Indications — What Venclexta is Used For
Venclexta is approved for:
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Acute Myeloid Leukemia (AML)
For detailed indication information refer to the NCI Venetoclax Drug Information.
Key Benefits of Venclexta
Targeted Mechanism of Action Venclexta specifically targets and inhibits BCL-2, a protein overexpressed in CLL and AML cells. This targeted approach causes cancer cell death while minimising damage to healthy cells compared to conventional chemotherapy.
Fixed-Duration Treatment Option Unlike many cancer treatments requiring indefinite therapy, Venclexta combined with certain agents offers fixed-duration treatment options — 12 months for previously untreated CLL/SLL and 24 months for relapsed/refractory CLL/SLL — allowing patients to complete treatment and discontinue.
Deep Remission Rates Clinical trials demonstrate that Venclexta achieves deep remissions including undetectable minimal residual disease (uMRD) in a significant proportion of patients, which is associated with improved long-term outcomes.
Oral Administration Venclexta is taken as a tablet once daily with food, offering convenience compared to intravenous chemotherapy regimens.
Strong Evidence Base Multiple Phase 3 trials across CLL, SLL, and AML have demonstrated Venclexta’s efficacy, making it one of the most well-studied targeted therapies in haematological oncology.
How Venclexta Works
Cancer cells in CLL, SLL, and AML overexpress the BCL-2 protein, which blocks the natural cell death pathway (apoptosis). This overexpression allows cancer cells to:
Venclexta (Venetoclax) works by:
This mechanism is described in detail in the MedlinePlus Venetoclax monograph.
Dosage and Administration
Dose Ramp-Up Schedule (CLL/SLL):
| Week | Daily Dose |
|---|---|
| Week 1 | 20mg once daily |
| Week 2 | 50mg once daily |
| Week 3 | 100mg once daily |
| Week 4 | 200mg once daily |
| Week 5 onwards | 400mg once daily (target dose) |
Full dosing guidelines are available at Drugs.com Venetoclax Dosage.
Important Safety Information — Tumour Lysis Syndrome (TLS)
The most serious risk with Venclexta is Tumour Lysis Syndrome (TLS) — a condition caused by the rapid breakdown of cancer cells that releases their contents into the bloodstream, which can cause kidney failure and other serious complications.
TLS risk is highest during the dose ramp-up period. To reduce TLS risk:
Detailed TLS monitoring and management guidelines are available from the American Society of Hematology.
Possible Side Effects
Common side effects include neutropenia (low white blood cell count), nausea, diarrhoea, anaemia, upper respiratory tract infection, fatigue, and thrombocytopenia (low platelet count).
Serious side effects include:
Full side effect information is available at FDA Venetoclax Safety Information.
Precautions and Drug Interactions
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Venclexta under manufacturer-recommended conditions, ensuring product integrity and efficacy for every supply.
Manufacturer Information
Venclexta (Venetoclax) is manufactured by AbbVie Inc., in partnership with Genentech/Roche. AbbVie holds exclusive rights to commercialise Venetoclax outside the United States. Venclexta received initial FDA approval in April 2016 for CLL with 17p deletion, with subsequent approvals for broader CLL/SLL indications and AML.
Related Cancer Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Venclexta used for? Venclexta (Venetoclax) is used to treat Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML). It is used alone or in combination with other medicines depending on the cancer type and treatment history. More information is available at Cancer.gov.
Q. What is the generic name of Venclexta? The generic name of Venclexta is Venetoclax. It belongs to the class of BCL-2 inhibitors and is a targeted cancer therapy rather than conventional chemotherapy.
Q. Is Venclexta available in India? Venclexta can be supplied to hospitals, oncology centres, clinics, and pharmacies in India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the price of Venclexta in India? Venclexta price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. What is the dose ramp-up schedule for Venclexta? Venclexta treatment starts at 20mg daily in week 1 and increases gradually each week to a target dose of 400mg daily by week 5. This gradual ramp-up is essential to reduce the risk of Tumour Lysis Syndrome (TLS).
Q. What is Tumour Lysis Syndrome and how is it managed? Tumour Lysis Syndrome (TLS) is a serious condition caused by rapid cancer cell death that releases cellular contents into the bloodstream. It is managed by ensuring adequate hydration, prophylactic allopurinol, blood chemistry monitoring, and in some high-risk cases, hospitalisation during dose ramp-up.
Q. How to order Venclexta from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements.
Q. Does A.K. Pharma supply Venclexta in bulk? Yes. A.K. Pharma supplies Venclexta in bulk to hospitals, oncology centres, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Q. Where can I find clinical evidence for Venclexta? Key Venclexta clinical trials including CLL14, MURANO, and VIALE-A are published in the New England Journal of Medicine. FDA approval information is available at FDA.gov.
Why Order Venclexta from A.K. Pharma?
Contact A.K. Pharma for Venclexta Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
